An In-Depth Pharmacological and Clinical Review of Inclisiran: A First-in-Class siRNA Therapeutic for Hypercholesterolemia

Executive Summary

Inclisiran, marketed under the brand name Leqvio®, represents a significant advancement in the management of hypercholesterolemia, establishing a new class of lipid-lowering therapies based on small interfering RNA (siRNA) technology. It is the first and only approved siRNA therapeutic designed to lower low-density lipoprotein cholesterol (LDL-C), a primary causal factor in the development of atherosclerotic cardiovascular disease (ASCVD). This report provides a comprehensive analysis of inclisiran, covering its molecular characteristics, novel mechanism of action, pharmacological profile, pivotal clinical trial evidence, safety and tolerability, global regulatory status, and its comparative positioning within the current therapeutic landscape.

The core innovation of inclisiran lies in its unique mechanism of action, which harnesses the natural cellular process of RNA interference (RNAi). It is specifically engineered to inhibit the hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that promotes the degradation of LDL receptors (LDLR). By preventing the translation of PCSK9 messenger RNA (mRNA), inclisiran effectively "turns off the tap" of PCSK9 production within the liver. This leads to an increased density of LDLRs on the hepatocyte surface, enhancing the clearance of LDL-C from the circulation. This intracellular mechanism of synthesis inhibition fundamentally distinguishes inclisiran from the existing class of PCSK9 monoclonal antibodies (mAbs), which act extracellularly by binding to and sequestering the already-secreted PCSK9 protein.

The clinical efficacy of inclisiran has been robustly demonstrated across the pivotal ORION phase III clinical trial program. In diverse populations of high-risk patients, including those with established ASCVD and heterozygous familial hypercholesterolemia (HeFH), inclisiran consistently achieved a potent and durable placebo-corrected reduction in LDL-C of approximately 50%. This effect is not only significant in magnitude but is also remarkably long-lasting, a direct consequence of its pharmacological mechanism.

This durability enables a revolutionary dosing regimen: after two initial loading doses at day 1 and month 3, inclisiran is administered as a subcutaneous injection by a healthcare professional just twice a year. This biannual schedule has profound implications for clinical practice, offering a powerful solution to the long-standing and pervasive challenge of patient non-adherence to daily oral medications, which is a primary driver of treatment failure in chronic cardiovascular disease management.

The safety profile of inclisiran has been favorable and consistent across its clinical development program. Adverse events are generally comparable to placebo, with the most common treatment-related effect being mild-to-moderate and transient injection-site reactions. Systemic adverse events are infrequent, a profile attributed to its liver-targeted design which minimizes systemic exposure.

Inclisiran has secured regulatory approval in major markets worldwide, including the United States, the European Union, the United Kingdom, and China. Its approved indications have progressively expanded, reflecting growing regulatory confidence in its safety and efficacy, positioning it as a key adjunct to statin therapy and an important option for statin-intolerant patients. However, the definitive data on its ability to reduce cardiovascular morbidity and mortality are still pending from large, ongoing cardiovascular outcome trials (CVOTs), most notably the ORION-4 study. The results of this trial will be a critical determinant of its ultimate place in therapeutic guidelines and its competitive standing against the PCSK9 mAbs, which already have proven cardiovascular outcome benefits. In the interim, inclisiran offers a compelling new option for potent and sustained LDL-C lowering, distinguished by a dosing schedule that could transform the paradigm of long-term lipid management.

Molecular Profile and Novel Mechanism of Action

Inclisiran represents a paradigm shift in lipid-lowering therapy, moving beyond traditional small molecules and protein-based biologics to harness the power of genetic medicine. Its design is a sophisticated fusion of nucleic acid chemistry and targeted delivery technology, enabling it to selectively silence a key gene involved in cholesterol metabolism with remarkable specificity and duration.

Chemical and Structural Characteristics

Inclisiran is a synthetically manufactured, chemically modified, double-stranded small interfering ribonucleic acid (siRNA).[1] It is classified as a biotech drug and an antilipemic agent within the Anatomical Therapeutic Chemical (ATC) classification system (code C10AX16).[3] It is also known by its developmental codes ALN-PCSsc and ALN-60212.[3]

The molecule's identity is defined by several key identifiers and properties, summarized in Table 1. Structurally, inclisiran consists of two separate RNA strands: a sense (passenger) strand of 21 nucleotides and an antisense (guide) strand of 23 nucleotides, which are complementary and form a duplex.[2] The precise sequence of the antisense strand is designed to be perfectly complementary to a specific region of the human mRNA that codes for the PCSK9 protein, ensuring high target specificity.[6]

A critical aspect of inclisiran's design is its extensive chemical modification. Unmodified RNA is notoriously unstable in biological fluids, subject to rapid degradation by nucleases. To overcome this, inclisiran incorporates a suite of modifications, including 2′-O-methyl, 2′-fluoro, and 2′-deoxy-ribonucleotide substitutions throughout its backbone.[6] These changes render the molecule resistant to degradation by endo- and exonucleases, ensuring it remains intact long enough to reach its target tissue. Additionally, phosphorothioate linkages are strategically placed at the ends of the strands. These linkages serve a dual purpose: they further protect against nuclease degradation and, importantly, facilitate the efficient loading of the siRNA into the RNA-induced silencing complex (RISC), the cellular machinery that executes gene silencing.[6]

The most innovative structural feature of inclisiran is the covalent attachment of a triantennary N-acetylgalactosamine (GalNAc) ligand to the 3′ end of the sense strand.[7] This GalNAc conjugate is not merely an add-on; it functions as a high-precision molecular "zip code" or homing device for the liver. It binds with high affinity and specificity to the asialoglycoprotein receptor (ASGPR), a protein that is abundantly and almost exclusively expressed on the surface of hepatocytes, the primary liver cells.[6] This targeted delivery system is the key to inclisiran's pharmacological profile, allowing for selective uptake by the liver while minimizing exposure to other tissues, thereby enhancing efficacy and improving the safety profile by reducing the risk of off-target effects.[6] This elegant solution obviated the need for the complex lipid nanoparticle delivery systems required by earlier generations of siRNA therapeutics, enabling simple subcutaneous administration.[6]

Table 1: Key Properties of Inclisiran

Property	Description
Generic Name	Inclisiran (and Inclisiran Sodium)
Brand Name	Leqvio®
Drug Class	Antilipemic Agent; Small Interfering RNA (siRNA)
Type	Biotech
DrugBank ID	DB14901 8
CAS Number	1639324-58-5 3
Molecular Formula	C529​H664​F12​N176​O316​P43​S6​ 3
Molar Mass	~16,300 g/mol (free acid); ~17,285 g/mol (sodium salt) 3
Structure	Double-stranded siRNA (21-mer sense, 23-mer antisense) conjugated to a triantennary N-acetylgalactosamine (GalNAc) ligand.2

The RNA Interference (RNAi) Pathway: A Step-by-Step Elucidation

Inclisiran functions by co-opting a natural, highly conserved, and Nobel Prize-winning biological process known as RNA interference (RNAi).[3] This endogenous pathway is used by cells to regulate gene expression by causing the sequence-specific degradation of mRNA molecules. Inclisiran is designed to enter this pathway and direct it to silence the gene for PCSK9. The process unfolds in a precise, multi-step cascade.

Step 1: Hepatocyte-Specific Uptake

Following subcutaneous injection, inclisiran travels through the interstitial space and enters the bloodstream. The GalNAc ligand on the molecule acts as a key, seeking out its lock—the ASGPR—on the surface of hepatocytes.6 The high-affinity binding between the GalNAc ligand and the ASGPR triggers receptor-mediated endocytosis, a process where the cell membrane engulfs the inclisiran-ASGPR complex, pulling it into the cell within a vesicle.7 This mechanism is incredibly efficient and specific, ensuring that the vast majority of the drug is rapidly delivered to its intended site of action: the liver.6

Step 2: Endosomal Release

Once inside the hepatocyte, the vesicle containing the inclisiran-ASGPR complex fuses with an endosome. Within this acidic compartment, the ASGPR is dissociated from inclisiran and recycled back to the cell surface, ready to capture more molecules, while the GalNAc ligand is degraded.6 The double-stranded siRNA is then gradually released from the endosome into the cytoplasm, the main compartment of the cell where protein synthesis occurs. This endosomal compartment may act as an intracellular reservoir, slowly releasing inclisiran over time and contributing to the drug's exceptionally long duration of action.6

Step 3: RISC Loading and Activation

In the cytoplasm, the inclisiran siRNA duplex is recognized and loaded into a large multi-protein complex called the RNA-induced silencing complex (RISC).3 During this activation process, an enzyme within RISC (known as Argonaute-2 or "slicer") cleaves and discards the sense (passenger) strand of the inclisiran duplex.6

Step 4: Catalytic mRNA Cleavage

The remaining antisense (guide) strand becomes an integral part of the now-active RISC. This active complex then acts like a guided missile, using the antisense strand as a template to scan the cytoplasm for mRNA molecules with a perfectly complementary sequence.7 When it finds and binds to the target PCSK9 mRNA, the "slicer" component of RISC is activated and cleaves the mRNA strand.3 This cleavage marks the mRNA for rapid degradation by cellular enzymes, effectively preventing it from being used as a template for protein synthesis by the ribosome. This mechanism is catalytic, meaning that once a single RISC-inclisiran complex has destroyed one copy of PCSK9 mRNA, it is released and can go on to find and destroy many more copies.3 This amplification of the silencing effect is a key reason for the potency and durability of inclisiran's action.

Downstream Biological Consequences: From Gene Silencing to LDL-C Reduction

The catalytic degradation of PCSK9 mRNA has a profound and direct impact on the liver's ability to manage cholesterol.

Inhibition of PCSK9 Synthesis

By destroying the genetic blueprint for the PCSK9 protein, inclisiran dramatically reduces the synthesis and subsequent secretion of PCSK9 from the liver.1 This mechanism of

synthesis inhibition is a fundamental departure from the mechanism of PCSK9 monoclonal antibodies. While mAbs act like a sponge to "mop up" existing PCSK9 protein in the bloodstream, inclisiran works upstream to "turn off the tap" at the source, preventing the protein from being made in the first place.[9]

The Role of PCSK9 in Cholesterol Homeostasis

To understand the impact of inhibiting PCSK9, it is essential to understand its normal function. PCSK9 is a serine protease secreted by the liver that plays a pivotal role as a negative regulator of cholesterol clearance.1 It circulates in the blood and binds to LDL receptors (LDLRs) on the surface of hepatocytes. The primary function of LDLRs is to capture LDL-C particles from the blood and bring them into the liver for processing. After releasing its LDL-C cargo inside the cell, the LDLR would normally be recycled back to the cell surface to capture more LDL-C. However, when PCSK9 is bound to the LDLR, the entire complex is targeted for degradation within the cell's lysosomes.1 This PCSK9-mediated destruction prevents the LDLR from being recycled, leading to a net reduction in the number of active LDLRs on the liver surface. Fewer receptors mean less capacity to clear LDL-C from the blood, resulting in higher circulating levels of "bad" cholesterol.8

Increased LDLR Recycling and Density

By silencing the production of PCSK9, inclisiran removes this key negative regulator from the system. With dramatically lower levels of PCSK9 protein, the degradation of LDLRs is significantly reduced.1 This allows the LDLRs to undergo their normal recycling pathway, returning to the hepatocyte surface after delivering their LDL-C cargo. The result is a marked increase in the density of functional LDLRs on the liver, substantially boosting the liver's capacity to bind and clear LDL-C from the circulation.6

Clinical Outcome: Potent and Sustained LDL-C Reduction

The enhanced hepatic clearance of LDL-C directly translates into the primary therapeutic goal: a potent, durable, and clinically significant reduction in the plasma concentration of LDL-C.7 The intracellular, catalytic, and long-lasting nature of the RISC-mediated gene silencing is the direct pharmacological basis for the biannual dosing schedule that makes inclisiran a unique therapeutic option.

Comprehensive Pharmacological Profile

The pharmacological profile of inclisiran is unique among lipid-lowering therapies and is a direct consequence of its siRNA-based mechanism and GalNAc-targeted delivery. Its pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body) are characterized by rapid hepatic uptake, a short plasma half-life, and an exceptionally long duration of action at the target site.

Pharmacokinetics (Absorption, Distribution, Metabolism, Excretion - ADME)

Absorption

Following a single subcutaneous injection of the recommended 284 mg dose, inclisiran is rapidly absorbed from the injection site into the systemic circulation. Maximum plasma concentrations (Cmax​) are typically reached at approximately 4 hours post-administration.6

Distribution

The distribution of inclisiran is dominated by its rapid and highly selective uptake into hepatocytes, mediated by the interaction of its GalNAc conjugate with the asialoglycoprotein receptor (ASGPR).6 This process is so efficient that plasma concentrations of inclisiran decrease rapidly, falling below the lower limit of quantification within 24 to 48 hours after administration.6 This pharmacokinetic behavior—a brief presence in the plasma followed by sequestration in the target organ—is a hallmark of GalNAc-siRNA conjugates. In the plasma, inclisiran is approximately 87% bound to proteins at clinically relevant concentrations, but this is of limited consequence given its rapid clearance from the circulation.8 Clinical studies have shown no evidence of drug accumulation in the plasma with repeated dosing according to the recommended schedule, which is expected given the long interval between maintenance doses.12

Metabolism

Inclisiran's metabolic pathway is fundamentally different from that of most small molecule drugs. As a nucleic acid-based therapeutic, it is primarily metabolized by cellular nucleases, which are ubiquitous enzymes that break down RNA and DNA.1 These enzymes cleave inclisiran into smaller, inactive nucleotide fragments of varying lengths, which can then be reused by the cell's natural metabolic pathways. Critically, inclisiran is not a substrate for, nor does it inhibit or induce, the cytochrome P450 (CYP450) family of enzymes or other common drug transporters.1 This metabolic profile is of immense clinical importance. The CYP450 system is responsible for the metabolism of a vast number of medications, including many used in cardiovascular medicine such as certain statins. By completely bypassing this system, inclisiran has a very low intrinsic potential for drug-drug interactions (DDIs). This simplifies prescribing for clinicians, as they do not need to be concerned about inclisiran altering the levels of other medications the patient may be taking, a significant practical advantage in patients who are often on complex polypharmacy regimens.

Excretion

The primary route of elimination for inclisiran and its metabolites is renal. Approximately 16% of an administered dose of inclisiran is cleared from the body via the kidneys.8 The terminal elimination half-life (

t1/2​) of inclisiran from the plasma is very short, calculated to be approximately 9 hours.[6] It is crucial to recognize that this plasma half-life is misleading if interpreted in the conventional sense. It largely reflects the rapid clearance of the drug from the circulation into the liver, not the duration of its biological effect. The true "pharmacological half-life" of inclisiran's effect is intracellular and lasts for many months, driven by the stability of the activated RISC complex within the long-lived hepatocytes. This disconnect between plasma pharmacokinetics and target-site pharmacodynamics is a fundamental principle of this class of therapeutics.

Pharmacodynamics and Clinical Efficacy

The pharmacodynamic effects of inclisiran are characterized by a rapid onset, a potent magnitude of LDL-C reduction, and an exceptionally sustained duration of action.

Onset of Action

The biological cascade initiated by inclisiran begins soon after it enters the hepatocytes. The subsequent reduction in PCSK9 levels and increase in LDLR density translates into a measurable clinical effect relatively quickly. A reduction in LDL-C levels can be observed as early as 14 days after the initial dose, with the LDL-lowering effect being clearly established by day 30.8

Magnitude of Effect

Across the comprehensive ORION clinical trial program, inclisiran has demonstrated a consistent and potent LDL-C lowering effect. When added to maximally tolerated statin therapy, inclisiran produces a mean placebo-corrected reduction in LDL-C of approximately 48% to 52%.8 In clinical trials, mean reductions of 48-51% were observed 30 to 60 days after a dose.8 This magnitude of effect is clinically significant and comparable to that achieved by the PCSK9 monoclonal antibodies.

Duration of Action

The most remarkable and clinically differentiating pharmacodynamic feature of inclisiran is its extended duration of action. Following the initial loading doses, a single maintenance dose provides a stable and sustained reduction in LDL-C that persists for the entire 6-month (180-day) dosing interval.8 For example, clinical trial data showed that LDL-C reduction was still approximately 53% at 180 days post-dose.8 This long-lasting effect is the direct result of the stability of the RISC-inclisiran complex. Once loaded into the RISC within the long-living hepatocytes, the antisense strand remains active for many months, continuously degrading newly synthesized PCSK9 mRNA.6 This sustained intracellular activity is the pharmacological foundation that enables the convenient and adherence-promoting biannual maintenance dosing regimen.9

Pivotal Clinical Trial Evidence: The ORION Program

The clinical development of inclisiran has been anchored by the comprehensive and robust ORION program. This series of trials was strategically designed to rigorously evaluate the efficacy and safety of inclisiran across a spectrum of high-risk patient populations, establishing the evidence base for its global regulatory approvals. The program's design reflects a modern approach to drug development, first securing approval based on a validated surrogate endpoint (LDL-C reduction) while concurrently conducting large-scale trials to assess its impact on hard clinical outcomes.

The ORION Clinical Development Program: An Overview

The ORION program comprises multiple Phase II and Phase III studies, as well as ongoing cardiovascular outcome trials (CVOTs), involving tens of thousands of patients worldwide.[17] The foundational Phase III trials—ORION-9, ORION-10, and ORION-11—were designed to demonstrate potent and durable LDL-C lowering.[19] Building on this evidence, the program includes large, ongoing CVOTs, such as ORION-4 and VICTORION-2, which are designed to definitively determine whether this LDL-C reduction translates into a reduction in major adverse cardiovascular events (MACEs) like heart attacks and strokes.[3]

Trial Design and Patient Populations of Key Phase III Studies

The three pivotal Phase III trials shared a common design framework but enrolled distinct patient populations to establish efficacy across the primary target indications.

Common Design Elements

All three studies—ORION-9, -10, and -11—were randomized, double-blind, placebo-controlled trials, the gold standard for clinical evidence.14 Participants were randomized in a 1:1 ratio to receive either subcutaneous inclisiran or a matching placebo. The dosing regimen was consistent across the trials: an initial dose on Day 1, a second loading dose at 3 months (Day 90), and subsequent maintenance doses every 6 months thereafter, up to the primary endpoint assessment at 18 months (Day 540).22 The administered dose of inclisiran was 284 mg, which is equivalent to 300 mg of its sodium salt form.23 A crucial aspect of the trial design was that the vast majority of patients (approximately 90%) were on a background of maximally tolerated statin therapy, positioning inclisiran as an add-on treatment.22

Specific Patient Populations

• ORION-9 (NCT03397121): This trial focused on a particularly high-risk group: 482 adults with Heterozygous Familial Hypercholesterolemia (HeFH).[14] HeFH is a genetic disorder characterized by lifelong, severely elevated LDL-C levels and a high risk of premature cardiovascular disease. The mean baseline LDL-C in this cohort was exceptionally high at 153 mg/dL, despite the fact that over half of the patients were also taking ezetimibe in addition to statins.[22]
• ORION-10 (NCT03399370): Conducted exclusively in the United States, this trial enrolled 1,561 adults with established clinical atherosclerotic cardiovascular disease (ASCVD), such as a prior heart attack or stroke.[14] This represents a core secondary prevention population. The mean baseline LDL-C level was 104.7 mg/dL, indicating that these patients were not at their therapeutic goal despite standard-of-care lipid-lowering therapy.[18]
• ORION-11 (NCT03400800): This study, conducted in Europe and South Africa, enrolled 1,617 adults. The population included patients with established ASCVD as well as those with "ASCVD risk-equivalents".[14] These risk-equivalent conditions included type 2 diabetes, a history of familial hypercholesterolemia, or a high 10-year risk of a cardiovascular event (≥20%) as calculated by the Framingham Risk Score or a similar tool.[22] The mean baseline LDL-C was 105.5 mg/dL, similar to the ORION-10 cohort.[18]

The inclusion of these diverse but uniformly high-risk populations was a strategic choice. It allowed the investigators to demonstrate the drug's efficacy not only in patients with established disease but also in those with genetic predispositions and high-risk primary prevention profiles. The remarkable consistency of the results across these different groups became a powerful testament to the robustness of inclisiran's mechanism of action.

Primary and Secondary Efficacy Endpoints: Consistent and Potent LDL-C Lowering

The primary objective of the Phase III program was to quantify the effect of inclisiran on LDL-C levels. To capture both the endpoint effect and the durability over time, the trials used two co-primary efficacy endpoints.[19]

Co-Primary Endpoints

1. Percentage change in LDL-C from baseline to Day 510 (17 months): This endpoint measured the effect of the drug at a single, late time point in the study.
2. Time-adjusted percentage change in LDL-C from baseline after Day 90 and up to Day 540: This endpoint provides a more comprehensive measure of the drug's effect over the entire maintenance period, averaging the LDL-C reduction across multiple time points.

The results from these trials, published in the New England Journal of Medicine, were strikingly consistent and demonstrated a powerful LDL-C lowering effect, as summarized in Table 2.[18]

Table 2: Summary of Pivotal Phase III ORION Trial Efficacy

Trial (Patient Population)	Baseline LDL-C (mg/dL)	Placebo-Corrected LDL-C Reduction at Day 510 (%)	Time-Averaged Placebo-Corrected LDL-C Reduction (Day 90-540, %)
ORION-9 (N=482, HeFH)	153.0 22	-47.9 22	-44.3 22
ORION-10 (N=1,561, ASCVD)	104.7 22	-52.3 22	-53.8 22
ORION-11 (N=1,617, ASCVD or Risk-Equivalent)	105.5 22	-49.9 22	-49.2 22
Pooled Analysis (N=3,660)	N/A	-50.7 6	N/A

All reductions are statistically significant (P < 0.001).[22]

In the ORION-9 trial with HeFH patients, inclisiran reduced LDL-C by 39.7% from baseline, while the placebo group saw an 8.2% increase, resulting in a net between-group difference of -47.9%.[22] Similarly powerful results were seen in the larger ASCVD trials, ORION-10 and ORION-11, with placebo-corrected reductions hovering around 50% for both primary endpoints.[18] These results confirmed that a twice-yearly maintenance dose of inclisiran provides a potent and durable reduction in LDL-C on top of standard-of-care statin therapy.

Beyond LDL-C, the trials also assessed effects on other atherogenic lipoproteins. Data from the earlier ORION-1 trial, and confirmed in the Phase III program, showed that inclisiran also produces significant and sustained reductions in other key cardiovascular risk markers, including non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and very-low-density lipoprotein cholesterol (VLDL-C).[24]

The Unresolved Question: Cardiovascular Outcomes

While the LDL-C reduction data are compelling, the ultimate validation for any lipid-lowering therapy is proof that it reduces the risk of clinical cardiovascular events. As of late 2024, the effect of inclisiran on cardiovascular morbidity and mortality has not yet been definitively established. This was noted as a "Limitation of Use" on the initial FDA approval label, signifying that its approval was based on its effect on a surrogate endpoint (LDL-C), not on hard clinical outcomes.[15]

Exploratory, post-hoc analyses of the combined ORION Phase III trials have provided some suggestive data. These analyses of non-adjudicated MACEs hinted at a potential for cardiovascular benefit, but these findings were not from pre-specified endpoints and lacked the statistical power to be conclusive.[3]

The definitive answer awaits the results of the large, dedicated CVOTs. The primary outcomes trial is ORION-4 (NCT03705234), a major study that has enrolled over 15,000 patients with established ASCVD in the UK and USA.[3] This trial is designed with sufficient power and duration to determine if the ~50% LDL-C reduction provided by inclisiran translates into a statistically significant reduction in heart attacks, strokes, and cardiovascular death. The results of ORION-4 are highly anticipated by the medical community and are expected to be reported around 2026. A second major CVOT,

VICTORION-2, is also underway to further bolster the evidence base.[3] The outcome of these trials will be pivotal, ultimately determining whether inclisiran ascends to become a cornerstone of cardiovascular prevention or remains a potent but secondary agent for LDL-C management.

Safety, Tolerability, and Risk Profile

A favorable safety and tolerability profile is paramount for any medication intended for long-term use in a broad population, particularly for a chronic, asymptomatic condition like hypercholesterolemia. The clinical development program for inclisiran has generated substantial data indicating that the drug is generally well-tolerated, with a safety profile largely comparable to placebo, a finding that is consistent with its liver-targeted pharmacological design.

Clinical Trial Safety Data and Common Adverse Reactions

The primary safety data for inclisiran come from a pooled analysis of the three pivotal, placebo-controlled Phase III trials (ORION-9, -10, and -11), which included 1,833 patients treated with inclisiran for a median duration of 18 months.[26]

Overall Profile and Most Common Adverse Event

Across these trials, the overall incidence of adverse events was similar between the inclisiran and placebo groups.19 The only consistently reported adverse reaction that occurred significantly more frequently with inclisiran was an injection site reaction. In the pooled data, some form of injection site reaction (including pain, redness, or rash) was reported in 8.2% of patients receiving inclisiran, compared to just 1.8% of those receiving placebo.26 These reactions were almost universally described as mild to moderate in severity and were transient, typically resolving within a few days and rarely leading to discontinuation of the drug.6 This localized effect is an expected consequence of a subcutaneously administered therapy and is a direct result of the drug's pharmacology. The targeted delivery mechanism rapidly sequesters the drug in the liver, minimizing systemic exposure and thus limiting the potential for widespread systemic side effects.

Other Reported Adverse Reactions

Other adverse reactions that were reported in at least 3% of inclisiran-treated patients and occurred more frequently than in the placebo group were generally mild and occurred at rates only slightly above placebo. These include:

• Arthralgia (joint pain): 5.0% with inclisiran vs. 3.9% with placebo.[26]
• Bronchitis: 4.3% with inclisiran vs. 3.5% with placebo.[17]

Hepatotoxicity Assessment

Given that the liver is the target organ for inclisiran, hepatic safety has been a key area of focus. Extensive monitoring in clinical trials has shown no evidence of clinically significant liver injury.1 The rates of elevation in liver enzymes (alanine aminotransferase and aspartate aminotransferase) were low (less than 1%) and were similar between the inclisiran and placebo groups. These elevations were invariably transient, mild-to-moderate, and were not accompanied by symptoms or jaundice. Since its approval and more widespread use, there have been no published reports of severe liver injury attributed to inclisiran therapy, leading to a likelihood score of "E" (unlikely cause of clinically apparent liver injury) in expert reviews.1 Nonetheless, regulatory agencies such as the Therapeutic Goods Administration (TGA) in Australia have requested ongoing monitoring of hepatotoxicity as part of post-market surveillance commitments.27

Muscle-Related Events

Myalgia and other muscle-related symptoms are a well-known concern with statins. In the inclisiran trials, the incidence of such events was comparable to placebo. However, one network meta-analysis that compared different PCSK9-targeting therapies found that the monoclonal antibodies evolocumab and alirocumab demonstrated a significant advantage over inclisiran with respect to the incidence of creatine kinase (a muscle enzyme) elevations greater than three times the upper limit of normal. This suggests that the mAbs may have a more favorable profile regarding muscle-related adverse effects, although more direct comparative data are needed.28

Special Populations, Contraindications, and Warnings

Contraindications

Leqvio is contraindicated in a very specific population: patients who have experienced a prior serious hypersensitivity reaction to inclisiran or any of the excipients in the formulation. Serious hypersensitivity reactions, including angioedema (a rapid swelling of the deep layers of the skin), have been observed in clinical practice, though they are rare.26

Pregnancy and Lactation

• Pregnancy: The treatment of hyperlipidemia is not generally considered necessary during pregnancy, as cholesterol and its derivatives are essential for normal fetal development. Based on its mechanism of action—which lowers circulating cholesterol—Leqvio may cause fetal harm. Therefore, it is recommended that the drug be discontinued as soon as a pregnancy is recognized.[14] Animal reproduction studies in rats and rabbits did not reveal any evidence of teratogenicity or embryo-fetal toxicity at doses many times the maximum recommended human dose.[15] In Australia, it is assigned Pregnancy Category B1, indicating it has been taken by a limited number of pregnant women without an observed increase in malformations.[3]
• Lactation: There are no data on the presence of inclisiran in human milk or its effects on the breastfed infant. Studies in lactating rats showed that inclisiran was present in their milk.[14] However, as inclisiran is a large oligonucleotide molecule with poor oral bioavailability, it is considered unlikely that the low levels potentially present in breast milk would be absorbed by the infant or cause adverse effects. Nevertheless, until more data are available, caution is advised, particularly when nursing a newborn or preterm infant.[4]

Renal and Hepatic Impairment

• Hepatic Impairment: No dose adjustment is required for patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment. There are no data available for patients with severe (Child-Pugh class C) hepatic impairment, and therefore, inclisiran should be used with caution in this population.[13]
• Renal Impairment: No dose adjustments are necessary for patients with mild, moderate, or severe renal impairment, or for patients with end-stage renal disease. However, clinical experience in patients with severe renal impairment is limited, and caution is advised. For patients on hemodialysis, it is recommended that dialysis not be performed for at least 72 hours after inclisiran administration, as the effect of dialysis on the drug's pharmacokinetics has not been studied.[13]

Immunogenicity and Long-Term Safety Considerations

Anti-Drug Antibodies (ADAs)

As with any biologic therapy, there is a potential for the body to develop an immune response and form anti-drug antibodies. In the pre-registration clinical trials, between 5% and 13% of patients treated with inclisiran developed ADAs.1 However, a critical finding was that the presence of these antibodies was not associated with any changes in the drug's efficacy (LDL-C lowering), its pharmacokinetic profile, or its safety profile. This suggests that, at present, these ADAs are not clinically meaningful.1 Nevertheless, long-term immunogenicity remains a topic of interest and is part of ongoing post-market safety surveillance.27

Emerging Safety Signals and Long-Term Vigilance

While the overall safety data from the controlled trials are reassuring, it is important to acknowledge that these trials had a median follow-up of approximately 1.5 to 2 years, which is relatively short for a therapy intended for lifelong administration.26 The full long-term safety profile will only become clear with extended real-world use and the completion of the multi-year cardiovascular outcome trials.

Some early signals from post-market pharmacovigilance analyses warrant attention. One disproportionality analysis of adverse event reporting databases suggested that inclisiran might be associated with a higher risk of certain events, such as respiratory and urinary tract infections and other renal/urinary disorders, when compared to PCSK9 monoclonal antibodies.[29] The authors of that analysis hypothesized that this could be related to inclisiran's unique intracellular mechanism, but they stressed that the findings are preliminary and require further investigation to establish causality. These signals underscore the importance of ongoing vigilance. While clinicians can be confident in the established short-to-medium-term safety of inclisiran, particularly its benign systemic profile, the story of its long-term safety is not yet fully written.

Global Regulatory Status and Prescribing Information

The journey of inclisiran from a novel investigational agent to a globally approved therapy has been rapid, reflecting the strength of its clinical data and the significant unmet need for more effective and convenient lipid-lowering treatments. Its regulatory approvals and evolving prescribing information tell a story of growing confidence in its role in cardiovascular risk reduction.

Approval Timelines and Global Reach

Inclisiran was developed by The Medicines Company, which was subsequently acquired by Novartis, under a licensing agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics.[3] This collaboration brought together the innovative science of RNAi with the global development and commercialization capabilities of a major pharmaceutical company.

The drug has achieved regulatory approval in key markets around the world in a relatively short timeframe:

• European Union (EMA): Leqvio received its first major approval from the European Medicines Agency in December 2020.[3]
• United Kingdom (NICE): Following its EU approval, it received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for use within the National Health Service (NHS) in August 2021.[3]
• United States (FDA): The U.S. Food and Drug Administration approved Leqvio in December 2021, designating it as a first-in-class medication.[3]
• Australia (TGA): Approval from the Therapeutic Goods Administration was granted in September 2021.[27]
• China (NMPA): The National Medical Products Administration approved inclisiran for use in China in August 2023, opening access to another major global market.[3]

Approved Indications and Label Evolution: A Story of Expanding Confidence

The approved indications for inclisiran have evolved since its initial launch, particularly in the United States. This evolution reflects a progressive build-up of regulatory confidence as more data and experience have accumulated.

European Indication

The EMA label provides a broad indication for use in adults with primary hypercholesterolemia (both heterozygous familial and non-familial forms) or mixed dyslipidemia, as an adjunct to diet.13 It can be used in several clinical scenarios:

1. In combination with a statin (with or without other lipid-lowering therapies) in patients who are unable to reach their LDL-C goals with the maximum tolerated dose of a statin.
2. Alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated.

United States Indication and its Evolution

The FDA's approval journey for inclisiran demonstrates a clear trajectory from a more restrictive initial indication to a broader one.

• Initial U.S. Indication (December 2021): The first approval was conservative, positioning Leqvio as an adjunct to diet and maximally tolerated statin therapy. Its use was restricted to two high-risk secondary prevention populations: adults with clinical ASCVD or adults with HeFH, who required additional lowering of LDL-C.[3] This represented a typical "foot-in-the-door" approval for a novel drug class.
• Expanded U.S. Indication (July 2023): A significant label expansion occurred in July 2023. The indication was broadened to the treatment of adults with primary hyperlipidemia (a wider category including primary hypercholesterolemia) as an adjunct to diet and statin therapy.[14] The removal of the "maximally tolerated" language was a key change, signaling that the drug could be used earlier in the treatment course and not just as a last resort. This expansion opened its use to a larger primary prevention population, such as patients with multiple risk factors like diabetes and hypertension who have not yet had a cardiovascular event.[17]
• Anticipated Future Label Update: Further label updates are anticipated. Based on the results of the V-MONO study, which showed efficacy as a monotherapy, Novartis is expected to secure a label that removes the requirement for concomitant statin therapy altogether. This would officially position inclisiran as a first-line monotherapy option, alongside diet and exercise, for certain patients with hypercholesterolemia, such as those who are statin-intolerant.[32]

This rapid label evolution over just a few years demonstrates how a drug with a strong and consistent data package can progressively expand its market access and move up in the established treatment algorithm.

Dosage, Administration, and Practical Considerations

The administration of inclisiran is unique among lipid-lowering therapies and is a central feature of its clinical profile.

Dosage Form and Strength

Leqvio is supplied as a sterile solution in a single-dose, prefilled syringe. Each syringe contains 284 mg of inclisiran in 1.5 mL of solution, which corresponds to a concentration of 189 mg/mL.8 The solution should be clear and colorless to pale yellow, and should be inspected for particulate matter or discoloration before use.26

Recommended Dosing Schedule

The dosing schedule is designed to establish and maintain a steady-state reduction in PCSK9 synthesis. The recommended regimen is:

• An initial 284 mg dose administered as a single subcutaneous injection.
• A second 284 mg dose administered 3 months later.
• Subsequent maintenance doses of 284 mg administered every 6 months thereafter.[1]

Administration

A key practical aspect of Leqvio is that it must be administered by a healthcare professional.1 It is not intended for self-administration by the patient. The injection is given subcutaneously (into the fatty tissue under the skin) in the abdomen, the upper arm, or the thigh. It should not be injected into areas with active skin disease, injury, sunburns, or inflammation.13 This requirement for professional administration is a double-edged sword. On one hand, it virtually guarantees adherence to the dosing schedule for patients who attend their appointments, a major advantage in a field plagued by non-adherence to daily pills.21 The biannual schedule can be conveniently synchronized with routine semi-annual physician visits.20 On the other hand, it creates a logistical burden for both the patient (who must travel to a clinic for an injection) and the healthcare system (which must establish efficient workflows for administration). The long-term success of inclisiran will depend not only on its clinical merits but also on the successful implementation of new care delivery models to make these biannual injections seamless.22

Management of Missed Doses

The prescribing information provides clear guidance on how to manage missed doses, which is crucial for a long-acting therapy:

• If a planned maintenance dose is missed by less than 3 months, the healthcare professional should administer the dose as soon as possible, and then the patient should resume their original 6-month dosing schedule.
• If a planned maintenance dose is missed by more than 3 months, the entire loading schedule must be restarted. The patient should receive a dose immediately, a second dose 3 months later, and then resume the every-6-month maintenance schedule from that point.[13]

Comparative Analysis and Therapeutic Positioning

Inclisiran enters a crowded but incompletely served field of lipid-lowering therapies. Its unique mechanism and dosing regimen position it as a disruptive force, but its place in the therapeutic armamentarium is defined by its relationship to existing standards of care, particularly statins and the PCSK9 monoclonal antibodies. The choice of therapy for a given patient involves a nuanced consideration of efficacy, safety, evidence for cardiovascular outcome reduction, cost, and, crucially, the practicalities of long-term administration and adherence.

Inclisiran vs. PCSK9 Monoclonal Antibodies (Evolocumab, Alirocumab)

Inclisiran and the PCSK9 monoclonal antibodies (mAbs) evolocumab (Repatha®) and alirocumab (Praluent®) share the same therapeutic target—PCSK9—but they inhibit it in fundamentally different ways. This leads to important distinctions in their clinical profiles, creating a classic clinical trade-off for physicians and patients. A detailed comparison is presented in Table 3.

Table 3: Comparative Profile: Inclisiran vs. PCSK9 Monoclonal Antibodies

Feature	Inclisiran (Leqvio®)	Evolocumab (Repatha®) / Alirocumab (Praluent®)
Mechanism of Action	Intracellular inhibition of PCSK9 synthesis (RNAi).10	Extracellular binding and neutralization of PCSK9 protein (mAb).28
Target	PCSK9 mRNA within hepatocytes.24	Circulating PCSK9 protein in the plasma.34
Dosing Frequency	Every 6 months (maintenance phase).26	Every 2 or 4 weeks.22
Administration	By a healthcare professional.26	Patient self-administration.35
LDL-C Reduction	~50%.18	~50-60%.23
Proven CV Outcome Reduction	No (Data pending from ORION-4 trial).3	Yes (FOURIER and ODYSSEY OUTCOMES trials demonstrated ~15% risk reduction).6
Key Adverse Events	Transient injection site reactions (pain, redness, rash).26	Nasopharyngitis, back pain, flu-like symptoms; rare but serious angioedema (Repatha).35
Pediatric Indication	No (Adults only).13	Yes (Repatha for HeFH/HoFH in children ≥10 years).35

The central distinction lies in the trade-off between convenience and evidence. The mAbs, evolocumab and alirocumab, have the unequivocal advantage of having completed large cardiovascular outcome trials (FOURIER and ODYSSEY OUTCOMES, respectively) that proved they reduce the risk of MACE by approximately 15% on top of statin therapy.[6] This provides clinicians with the certainty that the LDL-C lowering translates into tangible clinical benefit. The cost of this certainty is a demanding administration schedule of self-injections every two or four weeks, which places a significant burden on the patient and is susceptible to non-adherence over the long term.[23]

Inclisiran offers the inverse proposition. Its greatest strength is its revolutionary dosing schedule of two professionally administered injections per year, which effectively solves the problem of medication adherence.[21] The trade-off is the current lack of definitive CVOT data. While it is widely expected that the potent and sustained LDL-C reduction will translate into a similar reduction in cardiovascular events, this remains an evidence-based extrapolation rather than proven fact until the ORION-4 results are available.[21]

In terms of efficacy, the two classes are broadly comparable. Network meta-analyses have found no significant difference in the magnitude of LDL-C reduction between inclisiran and the mAb class at 24 weeks, with both achieving reductions in the 50-60% range.[34] Some analyses suggest evolocumab may be slightly more potent, but for clinical purposes, they are considered to be in the same efficacy tier.[39] Their safety profiles are also both favorable, though they differ in character. Inclisiran's side effects are primarily localized to the injection site, whereas the mAbs are associated with a slightly higher rate of systemic effects like nasopharyngitis.[26]

Positioning Relative to Statins and Ezetimibe

Statins remain the undisputed cornerstone of lipid-lowering therapy due to their proven efficacy, oral administration, low cost, and vast body of evidence demonstrating cardiovascular risk reduction. Inclisiran is not intended to replace statins but to serve as a powerful complementary therapy.

Current Role

The primary role for inclisiran is as an add-on therapy for patients who are not at their LDL-C goal despite receiving a maximally tolerated dose of a statin, with or without the addition of ezetimibe.3 This includes a large number of high-risk patients with ASCVD or HeFH. A second, crucial role is in the management of patients who are genuinely statin-intolerant and cannot take these first-line agents. The European label is explicit about this use case, and the evolving US label is moving to formally accommodate it as a monotherapy option.13

Future Role

The future positioning of inclisiran is highly dependent on the outcomes of the ORION-4 trial. If the trial is positive and demonstrates a MACE reduction comparable to that of the PCSK9 mAbs, its superior adherence profile could make it the preferred second-line agent after statins. It could leapfrog ezetimibe in the treatment algorithm for high-risk patients due to its greater potency and guaranteed adherence. Furthermore, a positive CVOT could open the door to its use as a primary prevention tool in select high-risk populations, potentially revolutionizing long-term cardiovascular care by shifting from a daily pill model to an infrequent, professionally administered intervention.

Future Outlook and Unmet Needs

The Adherence Advantage

The single greatest potential advantage of inclisiran is its ability to address the pervasive problem of medication non-adherence. For chronic, asymptomatic conditions, long-term adherence to daily oral medications is notoriously poor, and this is a primary reason why a large proportion of high-risk patients fail to achieve and maintain their LDL-C goals.21 By shifting the responsibility of administration from the patient to the healthcare provider within a "vaccine-like" biannual schedule, inclisiran offers a novel and potentially transformative solution to this challenge.22 This could lead to better long-term LDL-C control at a population level.

The CVOT Imperative

As highlighted throughout this report, the future trajectory of inclisiran is inextricably linked to the results of its cardiovascular outcome trial. A positive result from ORION-4 would validate the adherence-centric model and likely position inclisiran as a dominant force in advanced lipid management. A neutral or negative result, while unlikely given the strong link between LDL-C and cardiovascular events, would severely curtail its use, relegating it to a niche role as a potent but purely cosmetic LDL-C lowering agent for patients in whom outcomes are not the primary concern.

Cost-Effectiveness

As a novel, branded biologic therapy, the cost of inclisiran is substantial and represents a significant barrier to widespread access.35 Payers will require robust cost-effectiveness analyses that demonstrate its value, not just in lowering a lab value, but in preventing expensive downstream events like heart attacks and hospitalizations. The economic value of improved adherence will be a key component of these analyses. Securing broad and favorable reimbursement will be crucial for its uptake in clinical practice.

Conclusions

Inclisiran (Leqvio®) is a landmark achievement in cardiovascular pharmacology, representing the successful clinical implementation of RNA interference technology for the treatment of a major public health problem. Its development from the fundamental discoveries of RNAi and the PCSK9 pathway to a globally approved medicine in under two decades is a testament to the power of targeted genetic medicine.

The core strengths of inclisiran are potent, consistent, and durable. Its novel mechanism of action—inhibiting PCSK9 synthesis at its source within the liver—results in a robust and sustained reduction in LDL-C of approximately 50% across diverse high-risk patient populations. This efficacy is coupled with a favorable safety profile, characterized primarily by mild and transient injection-site reactions, a direct benefit of its hepatocyte-specific delivery system that minimizes systemic drug exposure.

The most transformative feature of inclisiran is its biannual maintenance dosing regimen. By shifting the paradigm of chronic disease management from daily patient-administered pills to infrequent healthcare professional-administered injections, inclisiran offers a powerful and elegant solution to the critical and persistent problem of medication non-adherence. This has the potential to ensure that a far greater proportion of high-risk patients achieve and, more importantly, maintain their LDL-C goals over the long term.

However, the therapeutic landscape is defined by evidence, and at present, inclisiran's profile has one critical, unresolved question: the lack of definitive data on cardiovascular outcome reduction. While PCSK9 monoclonal antibodies have proven their ability to reduce heart attacks and strokes in large clinical trials, the corresponding evidence for inclisiran is still forthcoming. The medical community awaits the results of the ORION-4 cardiovascular outcome trial with great anticipation, as its findings will ultimately define inclisiran's place in treatment guidelines and its competitive standing.

In conclusion, inclisiran is a potent and well-tolerated LDL-C lowering therapy with a uniquely advantageous dosing profile that promises to overcome the challenge of non-adherence. It is currently a valuable tool for patients who are not at their LDL-C goal on statins or who are statin-intolerant. Its future as a potential cornerstone of cardiovascular prevention hinges on the demonstration of a clear benefit in reducing clinical events. Should the forthcoming outcome trials prove positive, inclisiran is poised to become a dominant force in lipid management, fundamentally altering the approach to long-term cardiovascular risk reduction for millions of patients worldwide.

Works cited

1. Inclisiran - LiverTox - NCBI Bookshelf, accessed August 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK588654/
2. Inclisiran - OEL Fastrac with ADE - Affygility Solutions, accessed August 4, 2025, https://affygility.com/oel/inclisiran.html
3. Inclisiran - Wikipedia, accessed August 4, 2025, https://en.wikipedia.org/wiki/Inclisiran
4. Inclisiran - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed August 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK576868/
5. CAS 1639324-58-5 Inclisiran - BOC Sciences, accessed August 4, 2025, https://www.bocsci.com/product/inclisiran-sodium-57828.html
6. Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran - American Heart Association Journals, accessed August 4, 2025, https://www.ahajournals.org/doi/10.1161/JAHA.123.032031
7. siRNA drug Leqvio (inclisiran) to lower cholesterol - PMC, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9802187/
8. Inclisiran: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 4, 2025, https://go.drugbank.com/drugs/DB14901
9. Inclisiran: a new generation of lipid-lowering siRNA therapeutic - PMC, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10611522/
10. What is the mechanism of action of Inclisiran sodium? - Patsnap Synapse, accessed August 4, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-action-of-inclisiran-sodium
11. What is the mechanism of Inclisiran? - Patsnap Synapse, accessed August 4, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-inclisiran
12. Mechanism of Action | LEQVIO® (inclisiran) | HCP, accessed August 4, 2025, https://www.leqviohcp.com/mechanism-of-action
13. Leqvio 284 mg solution for injection in pre filled syringe - Summary of Product Characteristics (SmPC) - (emc) | 12039, accessed August 4, 2025, https://www.medicines.org.uk/emc/product/12039/smpc
14. Inclisiran (Leqvio) - Keystone First VIP Choice, accessed August 4, 2025, https://www.keystonefirstvipchoice.com/content/dam/keystone-first/vip-choice/pdf/provider/resources/pharmacy/policies-20240801/Inclisiran_(Leqvio).pdf.coredownload.inline.pdf
15. LEQVIO® (inclisiran) injection, for subcutaneous use - accessdata.fda.gov, accessed August 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf
16. Cholesterol-Lowering Injection | LEQVIO® (inclisiran), accessed August 4, 2025, https://www.leqvio.com/
17. US FDA approves expanded indication for Novartis Leqvio ..., accessed August 4, 2025, https://www.novartis.com/us-en/news/media-releases/us-fda-approves-expanded-indication-novartis-leqvio-inclisiran-include-treatment-adults-high-ldl-c-and-who-are-increased-risk-heart-disease
18. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/32187462/
19. Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy, accessed August 4, 2025, https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-three-pivotal-trials-showing-durable-and-potent-efficacy-inclisiran-investigational-first-class-sirna-cholesterol-lowering-therapy
20. Two-Dose a Year LDL-lowering Drug Had Significant Impact in Pooled Analysis of ORION Trials - Diagnostic and Interventional Cardiology, accessed August 4, 2025, https://www.dicardiology.com/content/two-dose-year-ldl-lowering-drug-had-significant-impact-pooled-analysis-orion-trials
21. (PDF) PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection - ResearchGate, accessed August 4, 2025, https://www.researchgate.net/publication/363455311_PCSK9_Inhibitor_Wars_How_Does_Inclisiran_Fit_in_with_Current_Monoclonal_Antibody_Inhibitor_Therapy_Considerations_for_Patient_Selection
22. Inclisiran Data in NEJM Prompt Talk of What Comes Next | tctmd.com, accessed August 4, 2025, https://www.tctmd.com/news/inclisiran-data-nejm-prompt-talk-what-comes-next
23. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/32197277/
24. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins | Circulation, accessed August 4, 2025, https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.034710
25. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial - Oxford Academic, accessed August 4, 2025, https://academic.oup.com/eurheartj/article/43/48/5047/6782272
26. LEQVIO® (inclisiran) injection, for subcutaneous use, accessed August 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214012s011lbl.pdf
27. Leqvio | Therapeutic Goods Administration (TGA), accessed August 4, 2025, https://www.tga.gov.au/resources/auspmd/leqvio
28. PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a systematic review and network meta-analysis - Frontiers, accessed August 4, 2025, https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1375040/full
29. Full article: A comparative analysis of the safety profiles between inclisiran and other PCSK9 inhibitors from real-world evidence – what have we learned recently? - Taylor & Francis Online, accessed August 4, 2025, https://www.tandfonline.com/doi/full/10.1080/14740338.2024.2438753
30. Leqvio | European Medicines Agency (EMA), accessed August 4, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio
31. Annotation of EMA Label for inclisiran and APOB, LDLR, PCSK9 - PharmGKB, accessed August 4, 2025, https://www.pharmgkb.org/labelAnnotation/PA166273581
32. FDA Approves Inclisiran (Leqvio) Label Update as First-Line Monotherapy in Hypercholesterolemia - HCPLive, accessed August 4, 2025, https://www.hcplive.com/view/fda-approves-inclisiran-leqvio-label-update-first-line-monotherapy-hypercholesterolemia
33. Inclisiran Completed Phase 3 Trials for Elevated Low-Density Lipoprotein Cholesterol / Atherosclerotic Cardiovascular Diseases / Atherosclerotic Cardiovascular Disease Risk Equivelents Health Services Research - DrugBank, accessed August 4, 2025, https://go.drugbank.com/drugs/DB14901/clinical_trials?conditions=DBCOND0137877%2CDBCOND0078488%2CDBCOND0158483&phase=3&purpose=health_services_research&status=completed
34. How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient, accessed August 4, 2025, https://d-nb.info/1274065917/34
35. Leqvio vs. Repatha: How Are They Different? - Verywell Health, accessed August 4, 2025, https://www.verywellhealth.com/leqvio-vs-repatha-which-is-better-8660560
36. How Do Medications like Praluent and Repatha Work to Lower Cholesterol - GoodRx, accessed August 4, 2025, https://www.goodrx.com/classes/pcsk9-inhibitors/pcsk9-inhibitors-reduce-cholesterol
37. Praluent vs Repatha: What's the difference? - Drugs.com, accessed August 4, 2025, https://www.drugs.com/medical-answers/praluent-repatha-difference-3550245/
38. THE COMPARATIVE EFFICACY OF INCLISIRAN, PCSK9 INHIBITING MONOCLONAL ANTIBODIES, AND EZETIMIBE FOR THE TREATMENT OF HIGH CHOLESTEROL IN ADULTS WITH OR AT RISK OF ASCVD: A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS - JACC Journals, accessed August 4, 2025, https://www.jacc.org/doi/10.1016/S0735-1097%2822%2902542-6
39. Effects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis - ResearchGate, accessed August 4, 2025, https://www.researchgate.net/publication/389416009_Effects_of_Inclisiran_Alirocumab_Evolocumab_and_Evinacumab_on_Lipids_A_Network_Meta-Analysis
40. PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/36087240/